File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pooled analysis of Helicobacter pylori eradication regimes in Asia

TitlePooled analysis of Helicobacter pylori eradication regimes in Asia
Authors
Issue Date2000
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 2000, v. 15 n. 9, p. 1007-1017 How to Cite?
AbstractBackground and Aims: Differences in Helicobacter pylori strains and their resistance to antimicrobials between Asian and Western countries may affect the success in eradicating this bacterium. Our objective was to systematically review the regimens that have been tested in Asia. Methods: Data on anti-H. pylori therapies reported from Asia in a large number of publications identified up to December 1998 were pooled into a few groups based on the combination of drugs used. A comparison of different groups was made by calculating the pooled eradication rates. Results: Seventy-three studies with 134 treatment arms were reviewed. Pooled eradication rates of dual, triple and quadruple therapies were 61.0, 86.5 and 93.4%, respectively. Proton pump inhibitor (PPI)-based combinations were more widely used and effective, with overall eradication rates of 90.7% in triple therapy and 93.4% in quadruple therapy. Bismuth combined with tetracycline and metronidazole also showed a high eradication rate of 92.0%. Conclusions: Proton pump inhibitor-based triple therapy with either clarithromycin, amoxycillin or metronidazole was one of the most commonly used and effective anti-H. pylori triple therapy regimens in Asia. The classical triple therapy with a bismuth, tetracycline and metronidazole combination has a similar efficacy. The results of anti-H. pylori treatment in Asia are not different from those in Western countries. (C) 2000 Blackwell Science Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/77963
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWang, WHen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-06T07:37:40Z-
dc.date.available2010-09-06T07:37:40Z-
dc.date.issued2000en_HK
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2000, v. 15 n. 9, p. 1007-1017en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77963-
dc.description.abstractBackground and Aims: Differences in Helicobacter pylori strains and their resistance to antimicrobials between Asian and Western countries may affect the success in eradicating this bacterium. Our objective was to systematically review the regimens that have been tested in Asia. Methods: Data on anti-H. pylori therapies reported from Asia in a large number of publications identified up to December 1998 were pooled into a few groups based on the combination of drugs used. A comparison of different groups was made by calculating the pooled eradication rates. Results: Seventy-three studies with 134 treatment arms were reviewed. Pooled eradication rates of dual, triple and quadruple therapies were 61.0, 86.5 and 93.4%, respectively. Proton pump inhibitor (PPI)-based combinations were more widely used and effective, with overall eradication rates of 90.7% in triple therapy and 93.4% in quadruple therapy. Bismuth combined with tetracycline and metronidazole also showed a high eradication rate of 92.0%. Conclusions: Proton pump inhibitor-based triple therapy with either clarithromycin, amoxycillin or metronidazole was one of the most commonly used and effective anti-H. pylori triple therapy regimens in Asia. The classical triple therapy with a bismuth, tetracycline and metronidazole combination has a similar efficacy. The results of anti-H. pylori treatment in Asia are not different from those in Western countries. (C) 2000 Blackwell Science Asia Pty Ltd.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.subject.meshAsia - epidemiologyen_HK
dc.subject.meshBismuth - therapeutic useen_HK
dc.subject.meshDrug Therapy, Combination - therapeutic useen_HK
dc.subject.meshHelicobacter Infections - drug therapy - epidemiologyen_HK
dc.subject.meshHelicobacter pylori - isolation & purificationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMetronidazole - therapeutic useen_HK
dc.subject.meshProton Pumps - antagonists & inhibitorsen_HK
dc.subject.meshTetracycline - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titlePooled analysis of Helicobacter pylori eradication regimes in Asiaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=15&spage=1007&epage=1016&date=2000&atitle=Pooled+analysis+of+Helicobacter+pylori+eradication+regimes+in+Asiaen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1440-1746.2000.02253.xen_HK
dc.identifier.pmid11059929-
dc.identifier.scopuseid_2-s2.0-0033792192en_HK
dc.identifier.hkuros61784en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033792192&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1007en_HK
dc.identifier.epage1017en_HK
dc.identifier.isiWOS:000089991300007-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridWang, WH=23390847100en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats